Opsumit Fails to Meet Primary Goal in Phase 3 Trial for PAH-Eisenmenger Syndrome
News, Pulmonary Hypertension
A Phase 3 trial assessing Actelion‘s Opsumit (macitentan) for the treatment of pulmonary arterial hypertension (PAH) due to Eisenmenger syndrome did not meet its primary objective of a change in exercise ... Read more